May 4, 2026 · Form 4 insider transaction
PureTech Health plc sold 40,000,000 shares of Seaport Therapeutics, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as conversion of a derivative and disclosed on an SEC Form 4, filed 2 days after the transaction.
Each share of Series A-1, Series A-2 and Series B Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.; PureTech LYT, Inc. is the record holder of all of the securities reported in this Form 4. PureTech Health LLC is the sole owner of PureTech LYT, Inc. PureTech Health plc is the sole member of PureTech Health LLC, and has the power to direct the voting and disposition of securities held by PureTech LYT, Inc. and PureTech Health LLC.